Learning Center

ISCT-Webinar: Clinical Impact Forum: CAR T-cells for Autoimmune Diseases

  • Register
    • Non-member - Free!
    • Member - Free!
    • Community Administrator - Free!
    • Emeritus Member - Free!
    • Industry Community - Free!
    • Industry Community Sub Account - Free!
    • Laboratory Member - Free!
    • Laboratory Technologist Sub Account - Free!
    • Laboratory Regular Member Sub Account - Free!
    • Laboratory Resident and Fellow Sub Account - Free!
    • Regular Member - Free!
    • Resident or Fellow Member - Free!
    • Student Member - Free!
    • Technologist Member - Free!

Chimeric Antigen Receptor (CAR) T-cell therapy has revolutionized the treatment of hematological cancers, and exciting research is now exploring its potential in autoimmune diseases like systemic lupus erythematosus. Join us for a dynamic panel discussion featuring a clinician-scientist, a regulatory expert, and a patient/advocate who will share the real-world challenges faced by those living with these conditions. Together, we’ll explore how CAR T-cells may offer new hope for patients with autoimmune diseases, the mechanisms behind their action, and the critical unmet needs they aim to address. We’ll also discuss the regulatory hurdles specific to CAR T-cell therapy in this field, and what’s needed to bring these treatments to patients. Don’t miss this opportunity to gain insights into one of the most promising developments in autoimmune disease treatment.

Thane Kubik

Cellular Therapy Fellow

University of Minnesota

Thane completed a Master's of Science at the Rockefeller University in New York City while on a Fulbright Fellowship. He completed medical school at the University of British Columbia and then AP/CP residency at the University of Calgary. He completed his transfusion medicine fellowship at Mayo Clinic and is currently a cellular therapy and regenerative medicine fellow at the University of Minnesota. He will be joining Alberta Precision Labs as transfusion and cell therapy physician in July and will oversee standard-of-care and investigational products.

Theodros (Teddy) Mamo

Resident Physician

The University of Minnesota

Teddy obtained his MD/PhD degree from the Mayo Clinic and is currently wrapping up a combined training in Clinical Pathology and Transfusion Medicine with a focus on Cell and Gene Therapies. Prior to this, he completed a Pediatric internship and a Post-doctoral fellowship in Cellular Therapy. For the last five years, he has trained under the mentorship of Dr. David McKenna, the Medical Director of the GMP facility at the University of Minnesota that supports a range of Cell and Gene therapy INDs. He has experience working with approved products and clinical trials, including gene-edited hematopoietic stem cells (HSCs), CAR-T cells and NK cells as well as various levels of expertise in developing tumor-infiltrating lymphocytes (TILs), Tregs and MSCs. 

Fabian Muller

Professor; Senior Attending Physician and Head of the CAR T cell Unit

University Hospital Erlangen

Prof. Müller obtained his MD in Freiburg, Germany and started his clinical education in Hamburg. With a focus on targeting malignant B cells from his early research career he did a postdoctoral fellowship with Dr. Ira Pastan, at the NCI on resistance to CD22-targeted therapy in ALL and aggressive lymphoma. After his post-doc he continued the work on B cell targeting in Erlangen, Germany using first antibody directed therapies and then CAR T cells with a focus on immunologic questions. As head of the CAR T cell unit he pioneers CAR T cell therapies in novel indications including solid tumors but also rheumatologic diseases.

Simona Stankeviciute

Vice President, Technical

Parexel

Simona Stankeviciute, MD, MSc, has a background in clinical and regulatory research and development. Dr. Stankeviciute's professional experience includes working as a clinician at the Hospital of Lithuanian University of Health Sciences Kauno klinikos, Clinical Expert for the European Medicines Agency (EMA) and served as an alternate member of the Committee for Medicinal Products for Human Use (CHMP). Currently she works at Parexel where she provides regulatory and clinical expertise, optimizing product development programs and serving as a trusted advisor to clients. During both her time at the agency and Parexel, she is working on a number of Cell and Gene projects.

Jacquie Hellowell

CAR T recipient and patient advocate with Blood Cancer UK

"At 18, I started my working life as a Biomedical Scientist in Haematology. I was diagnosed with Systemic Lupus Erythematosus at 27 and had an anti-dsDNA at >300 in 2018. In 2019, at 57, I was diagnosed with Diffuse Large B Cell Lymphoma and received 4 lots of chemotherapy and radiotherapy treatments, meaning that I had 2 relapses. After the 2nd relapse, I was privileged to be selected to have CAR-T cell therapy. My T cells were trained to kill the cancerous B cells, and I was given them back on 16/2/22 (an exciting day as a former Biomedical Scientist!). My cells did their big job in 28 days! My clinician told me I was in the Goldilocks zone (not too hot, not too cold) after 2 weeks and I am still in the Goldilocks zone now over 3 years later. In addition, my dsDNA is now at 20 so no Lupus treatment needed. I do lots of voluntary work as a CAR-T advocate with Blood Cancer UK, and I was the Patient Case Study in their Action Plan presented at Westminster in September 2024."

Key:

Complete
Failed
Available
Locked
Clinical Impact Forum: CAR T-cells for Autoimmune Diseases
Open to view video.
Open to view video. Chimeric Antigen Receptor (CAR) T-cell therapy has revolutionized the treatment of hematological cancers, and exciting research is now exploring its potential in autoimmune diseases like systemic lupus erythematosus. Join us for a dynamic panel discussion featuring a clinician-scientist, a regulatory expert, and a patient/advocate who will share the real-world challenges faced by those living with these conditions. Together, we’ll explore how CAR T-cells may offer new hope for patients with autoimmune diseases, the mechanisms behind their action, and the critical unmet needs they aim to address. We’ll also discuss the regulatory hurdles specific to CAR T-cell therapy in this field, and what’s needed to bring these treatments to patients. Don’t miss this opportunity to gain insights into one of the most promising developments in autoimmune disease treatment.
Webinar Feedback form
10 Questions
Certificate of Webinar Participation
No credits available  |  Certificate available
No credits available  |  Certificate available Please complete the Webinar Feedback Form to get this certificate.
Quiz
5 Questions  |  Unlimited attempts  |  4/5 points to pass
5 Questions  |  Unlimited attempts  |  4/5 points to pass
Certificate of Webinar Completion
No credits available  |  Certificate available
No credits available  |  Certificate available Please complete the Learning Assessment to get this certificate.